L
Lila Bouadma
Researcher at University of Paris
Publications - 160
Citations - 12260
Lila Bouadma is an academic researcher from University of Paris. The author has contributed to research in topics: Intensive care & Medicine. The author has an hindex of 42, co-authored 129 publications receiving 9160 citations. Previous affiliations of Lila Bouadma include Paris Diderot University & Claude Bernard University Lyon 1.
Papers
More filters
Journal ArticleDOI
Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome
Alain Combes,David Hajage,Gilles Capellier,Alexandre Demoule,Sylvain Lavoué,Christophe Guervilly,Daniel da Silva,Lara Zafrani,Patrice Tirot,Benoit Veber,Eric Maury,Bruno Levy,Yves Cohen,Christian Richard,Pierre Kalfon,Lila Bouadma,Hossein Mehdaoui,Gaetan Beduneau,Guillaume Lebreton,Laurent Brochard,Niall D. Ferguson,Eddy Fan,Arthur S. Slutsky,Daniel Brodie,Alain Mercat +24 more
TL;DR: Among patients with very severe ARDS, 60‐day mortality was not significantly lower with ECMO than with a strategy of conventional mechanical ventilation that included ECMO as rescue therapy, and fewer cases of ischemic stroke.
Journal ArticleDOI
Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial.
Alain Mercat,Jean-Christophe M. Richard,Bruno Vielle,Samir Jaber,David Osman,Jean-Luc Diehl,Jean-Yves Lefrant,Gwenaël Prat,Jack Richecoeur,Ania Nieszkowska,Claude Gervais,Jérôme Baudot,Lila Bouadma,Laurent Brochard +13 more
TL;DR: A strategy for setting PEEP aimed at increasing alveolar recruitment while limiting hyperinflation did not significantly reduce mortality, but it did improve lung function and reduced the duration of mechanical ventilation and theduration of organ failure.
Journal ArticleDOI
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.
Lila Bouadma,Charles-Edouard Luyt,Florence Tubach,Christophe Cracco,Antonio Alvarez,Carole Schwebel,Frédérique Schortgen,Sigismond Lasocki,Benoit Veber,Monique Dehoux,Maguy Bernard,Blandine Pasquet,Bernard Regnier,Christian Brun-Buisson,Jean Chastre,Michel Wolff +15 more
TL;DR: A procalcitonin-guided strategy to treat suspected bacterial infections in non-surgical patients in intensive care units could reduce antibiotic exposure and selective pressure with no apparent adverse outcomes.
Journal ArticleDOI
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
François-Xavier Lescure,François-Xavier Lescure,Lila Bouadma,Lila Bouadma,Duc Bao Nguyen,Marion Parisey,Paul-Henri Wicky,Paul-Henri Wicky,Sylvie Behillil,Alexandre Gaymard,M. Bouscambert-Duchamp,Flora Donati,Quentin Le Hingrat,Quentin Le Hingrat,Vincent Enouf,Nadhira Houhou-Fidouh,M. Valette,Alexandra Mailles,Jean-Christophe Lucet,Jean-Christophe Lucet,Xavier Duval,Xavier Duval,Diane Descamps,Diane Descamps,Denis Malvy,Jean-François Timsit,Jean-François Timsit,Bruno Lina,Sylvie van-der-Werf,Yazdan Yazdanpanah,Yazdan Yazdanpanah +30 more
TL;DR: The relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020, are reported and will contribute to advances in the implementation of more efficient infection control strategies.
Journal ArticleDOI
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Philipp Schuetz,Yannick Wirz,Ramon Sager,Mirjam Christ-Crain,Daiana Stolz,Michael Tamm,Lila Bouadma,Charles Edouard Luyt,Michel Wolff,Jean Chastre,Florence Tubach,Kristina B. Kristoffersen,Olaf Burkhardt,Tobias Welte,Stefan Schroeder,Vandack Nobre,Long Wei,Heiner C. Bucher,Neera Bhatnagar,Djillali Annane,Konrad Reinhart,Angela Branche,Pierre Damas,Maarten W. N. Nijsten,Dylan W. de Lange,Rodrigo Octavio Deliberato,Stella Ss Lima,Vera Maravic-Stojkovic,Alessia Verduri,Bin Cao,Yahya Shehabi,Albertus Beishuizen,Jens-Ulrik Stæhr Jensen,Caspar Corti,Jos A H van Oers,Ann R. Falsey,Evelien de Jong,Carolina F. Oliveira,Bianca Beghe,Matthias Briel,Beat Mueller +40 more
TL;DR: In this article, a systematic review included individual patient data from 14 randomised controlled trials with a total of 4211 participants and found no increased risk for all-cause mortality or treatment failure when procalcitonin was used to guide initiation and duration of antibiotic treatment in participants with acute respiratory infections compared to control participants.